Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,307 shares of the conglomerate's stock, valued at approximately $1,012,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BlackRock Inc. acquired a new position in Danaher in the 2nd quarter worth $10,492,520,000. State Street Corp boosted its position in shares of Danaher by 1.7% during the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate's stock worth $6,345,529,000 after buying an additional 472,608 shares during the period. Capital International Investors grew its holdings in shares of Danaher by 8.9% during the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate's stock worth $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate's stock worth $3,656,595,000 after buying an additional 1,334,221 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Danaher by 11.2% in the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate's stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have weighed in on DHR. Weiss Ratings raised Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, July 15th. Evercore restated an "outperform" rating and set a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Guggenheim lowered their target price on Danaher from $235.00 to $200.00 and set a "buy" rating on the stock in a research report on Wednesday, July 22nd. Royal Bank Of Canada upped their target price on Danaher from $200.00 to $215.00 and gave the stock an "outperform" rating in a report on Wednesday, July 22nd. Finally, DZ Bank started coverage on Danaher in a research report on Wednesday, June 3rd. They set a "buy" rating and a $210.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average price target of $228.91.
Get Our Latest Stock Report on DHR
Danaher Stock Up 0.3%
DHR stock opened at $216.41 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $152.13 billion, a PE ratio of 38.44, a PEG ratio of 2.69 and a beta of 0.78. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The business's 50 day simple moving average is $199.46 and its 200 day simple moving average is $192.52.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the firm posted $0.77 EPS. The company's quarterly revenue was up 5.5% on a year-over-year basis. As a group, research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.
Danaher Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
